Fig. 2.

Survival, readmission, and patient-reported clinical trajectory following melioidosis. A: Survival of enrolled patients stratified by age. P < 0.0001 by the logrank test. B: Survival of patients discharged from hospital alive stratified by age. P < 0.0001 by the logrank test. C: Cumulative incidence of hospital readmission in patients discharged from hospital alive stratified by age. D: Overall condition since discharge and use of TMP-SMX reported by patients alive and contacted at each follow up time point. For A–C: Red line, 15–30 years; blue line, 31–50 years; green line, 51–70 years; purple line, >70 years.